Frederik Lars Giesel
Overview
Explore the profile of Frederik Lars Giesel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rathke H, Winter E, Bruchertseifer F, Rohrich M, Giesel F, Haberkorn U, et al.
J Nucl Med
. 2024 Jun;
65(7):1057-1063.
PMID: 38844358
The aim of this work is to evaluate our clinical real-world data obtained with Ac-PSMA-617 (AcPSMA), which were acquired under compassionate care regulations in patients with advanced-stage prostate cancer. The...
2.
Zippel C, Wirth P, Biedenstein S, Weismuller A, Weigen-Schauer H, Moustafa S, et al.
Rofo
. 2024 Jan;
196(8):828-833.
PMID: 38237632
No abstract available.
3.
Krilaviciute A, Becker N, Lakes J, Radtke J, Kuczyk M, Peters I, et al.
Eur Urol Oncol
. 2023 Oct;
6(6):566-573.
PMID: 37806841
Background: Annual digital rectal examination (DRE) is recommended as a stand-alone screening test for prostate cancer (PCa) in Germany for 45+ yr olds. DRE diagnostic performance in men as young...
4.
Morawitz J, Bruckmann N, Jannusch K, Dietzel F, Milosevic A, Bittner A, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509307
This study compares the diagnostic potential of conventional staging (computed tomography (CT), axillary sonography and bone scintigraphy), whole-body magnetic resonance imaging (MRI) and whole-body F-fluorodeoxyglucose positron emission tomography (F-FDG PET/)MRI...
5.
Aso A, Nabetani H, Matsuura Y, Kadonaga Y, Shirakami Y, Watabe T, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37240044
Fibroblast activation proteins (FAP) are overexpressed in the tumor stroma and have received attention as target molecules for radionuclide therapy. The FAP inhibitor (FAPI) is used as a probe to...
6.
Drewes L, Boschheidgen M, Sommer B, Radtke J, Lopez-Cotarelo C, Giesel F, et al.
Rofo
. 2023 Mar;
195(7):616-619.
PMID: 36928521
No abstract available.
7.
David S, Krieg S, Esposito I, Schott M, Giesel F, Roderburg C, et al.
Horm Metab Res
. 2023 Feb;
55(4):227-235.
PMID: 36828028
The prognostic stratification of the current AJCC/UICC TNM classification for adrenocortical carcinoma (ACC) has been validated in only a few studies. In this study, it was hypothesized that redefining the...
8.
Gehling K, Mokry T, Do T, Giesel F, Dietrich S, Haberkorn U, et al.
Rofo
. 2022 Feb;
194(7):747-754.
PMID: 35211927
Purpose: In patients with malignant lymphoma, disease activity is recommended to be assessed by FDG-PET/CT and the Deauville five-point scale (5-PS). The purpose of this study was to explore the...
9.
Kratochwil C, Haberkorn U, Giesel F
Semin Nucl Med
. 2020 Mar;
50(2):133-140.
PMID: 32172798
Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-emitting Lutetium has already been investigated in several early phase dosimetry studies, demonstrated promising results in phase-2, and recently the first phase-3 trial...
10.
Khreish F, Rosar F, Kratochwil C, Giesel F, Haberkorn U, Ezziddin S
Eur J Nucl Med Mol Imaging
. 2019 Dec;
47(8):2040-2041.
PMID: 31814067
No abstract available.